Genzyme — Merger or Acquisition (February 2011)
15 slides from Genzyme's merger presentation, Feb 16, 2011
Slide 1: Adding a New Global Platform to our Sustainable Growth Strategy
Adding a New Global Platform to our Sustainable Growth Strategy February 16, 2011
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under
Slide 3: Conference Call Speakers
Conference Call Speakers sanofi-aventis Christopher A. Viehbacher Chief Executive Officer Jérôme Contamine Executive Vice President, Chief Financial Officer Genzyme Henri A. Termeer Chairman of the Board, President, Chief Executive Officer
Slide 4: Rationale for sanofi-aventis
Rationale for sanofi-aventis Christopher A. Viehbacher Chief Executive Officer
Slide 5: Strategically Consistent and Financially Attractive Acquisition for sanofi-aventis
A Strategically Consistent and Financially Attractive Acquisition for sanofi-aventis Creates a meaningful new growth platform Expands our footprint in biotechnology Increases our U.S. presence Bolts on to our existing business Significantly contributes to our goal of sustainable earnings growth Driv
Slide 6: Rationale for Genzyme
Rationale for Genzyme Henri A. Termeer Chairman of the Board, President, CEO
Slide 7: The Right Transaction for Genzyme, its Shareholders, and Other Stakeholders
The Right Transaction for Genzyme, its Shareholders, and Other Stakeholders Represents a new beginning for Genzyme Tremendous value recognized by sanofi-aventis in our record of innovation in our unique and pioneering approach to serving patients Shared exciting vision of the future in which Genzyme
Slide 8: Transaction Overview
Transaction Overview Jérôme Contamine Executive Vice President, Chief Financial Officer
Slide 9: Sanofi-aventis to Acquire Genzyme
Sanofi-aventis to Acquire Genzyme $74.00 per share in cash plus contingent value right (CVR) Risk / reward on Lemtrada™ and sustained production of Cerezyme® and Fabrazyme® shared through CVR structure CVR security to be publicly traded Transaction unanimously approved by both Boards of Directors No
Slide 10: CVR Structure
Production Milestone Approval Milestone Sales Milestone #1 Sales Milestone #2 Sales Milestone #3 Sales Milestone #4 Cash Payments Triggers Estimated Timing of Potential Payments CVR Structure (1) $1.00 per CVR $1.00 per CVR $2.00 per CVR $3.00 per CVR $4.00 per CVR $3.00 per CVR Paid if specified Ce
Slide 11: Genzyme Acquisition Delivers Significant Financial Benefits
Genzyme Acquisition Delivers Significant Financial Benefits Revenue growth acceleration Genzyme to benefit from sanofi-aventis’ extensive resources and experience in manufacturing Significant Business EPS accretion expected: Accretive in Year 1 after closing Accretion of € 0.75 to € 1.00 by (1) Valu
Slide 12: Transaction valued at $20.1bn, excluding CVR component
Transaction valued at $20.1bn , excluding CVR component Net cash position of Genzyme: ~$800m by end of Fully financed upfront cash transaction Bridge facilities ( $10bn to be refinanced by bond issuance and $5bn to be refinanced by cash flow) Cash and/or issuance of commercial paper Attractive cost
Slide 13: Next Steps
Next Steps Christopher A. Viehbacher Chief Executive Officer
Slide 14: A Clear Path Forward given Antitrust Clearance already Granted in the U.S. and EU
Legal process Tender offer, CVR registration Planning Integration A Clear Path Forward given Antitrust Clearance already Granted in the U.S. and EU Q1 Q2 Q3 Feb 16 Merger announcement Early Q2 Anticipated closing Mid Feb Kick-off Legal process Pre-integration process Integration process Day 1
Slide 15: sanofi aventis
sanofi aventis Because health macters